United-Guardian (NASDAQ:UG – Get Free Report) is one of 894 publicly-traded companies in the “Pharmaceuticals” industry, but how does it weigh in compared to its rivals? We will compare United-Guardian to related businesses based on the strength of its earnings, analyst recommendations, institutional ownership, risk, profitability, valuation and dividends.
Profitability
This table compares United-Guardian and its rivals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| United-Guardian | 25.16% | 27.80% | 23.82% |
| United-Guardian Competitors | -2,380.61% | -219.90% | -15.56% |
Dividends
United-Guardian pays an annual dividend of $0.60 per share and has a dividend yield of 6.6%. United-Guardian pays out 88.2% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. As a group, “Pharmaceuticals” companies pay a dividend yield of 3.3% and pay out 48.0% of their earnings in the form of a dividend. United-Guardian has increased its dividend for 1 consecutive years.
Institutional & Insider Ownership
23.2% of United-Guardian shares are owned by institutional investors. Comparatively, 32.7% of shares of all “Pharmaceuticals” companies are owned by institutional investors. 29.0% of United-Guardian shares are owned by insiders. Comparatively, 14.2% of shares of all “Pharmaceuticals” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Analyst Recommendations
This is a breakdown of recent ratings and target prices for United-Guardian and its rivals, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| United-Guardian | 0 | 1 | 0 | 0 | 2.00 |
| United-Guardian Competitors | 7776 | 13771 | 25740 | 1037 | 2.41 |
As a group, “Pharmaceuticals” companies have a potential upside of 24.97%. Given United-Guardian’s rivals stronger consensus rating and higher probable upside, analysts plainly believe United-Guardian has less favorable growth aspects than its rivals.
Volatility and Risk
United-Guardian has a beta of 0.99, indicating that its stock price is 1% less volatile than the S&P 500. Comparatively, United-Guardian’s rivals have a beta of -3.81, indicating that their average stock price is 481% less volatile than the S&P 500.
Valuation and Earnings
This table compares United-Guardian and its rivals revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| United-Guardian | $12.44 million | $2.11 million | 13.35 |
| United-Guardian Competitors | $3.57 billion | $3.20 billion | 552.48 |
United-Guardian’s rivals have higher revenue and earnings than United-Guardian. United-Guardian is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
Summary
United-Guardian rivals beat United-Guardian on 9 of the 15 factors compared.
About United-Guardian
United-Guardian, Inc. is a specialty chemicals company that develops, manufactures and markets products for the personal care, pharmaceutical and industrial markets. The company serves customers in the United States and international markets through direct sales, distributors and commercial partners. Its personal care portfolio includes Lubrajel, a family of water-based moisturizing and lubricating gels used in skin-care, hair-care, cosmetic and personal lubricant formulations. United-Guardian also supplies specialty ingredients designed to improve the texture, moisture retention and performance of finished consumer products.
Receive News & Ratings for United-Guardian Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United-Guardian and related companies with MarketBeat.com's FREE daily email newsletter.
